alexa Metavert For Treating Pancreatic Cancer | 62400
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

14th World Cancer & Anti-Cancer Therapy Convention
November 21-23, 2016 Dubai, UAE

Mouad Edderkaou, C Chheda, B Soufi, R Murali and S J Pandol
Cedars-Sinai Medical Center, USA
ScientificTracks Abstracts: J Cancer Sci Ther
DOI: 10.4172/1948-5956.C1.093
Abstract
Background & Aim: Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with no effective treatment. PDAC cells are highly proliferative and metastatic. We have developed a new drug called Metavert that targets at the same time the glycogen synthase kinase 3 beta (GSK-3β) and histone deacetylase (HDAC), important mediators of cancer progression. The aim of this study was to test this agent for treatment of PDAC. Methods: PDAC cell lines, patient-derived circulating tumor cells (CTCs), and normal cells were treated with different doses of Metavert and cell survival, apoptosis, epithelial to mesenchymal transition (EMT) markers, and invasion ability were measured. Treatments were performed alone and in combination with gemcitabine or exposure to irradiation. In vivo, KrasLSL-G12D/+; Trp53LSL-R172H/+; and Pdxcre (KPC) mice were intra-peritoneally injected with Metavert (5mg/Kg) 3 times per week from age 2 months until death. Survival and number of metastasis were determined. Pancreatic lesions and tumor grades as well as fibrosis and inflammation were measured by immunohistochemistry. Cytokine production and expression of cytokine receptors were measured in tumor cells and in cells present in the tumor microenvironment. Results: Metavert significantly (at nano-molar concentrations) decreased cancer cell survival and increased apoptosis in several PDAC cells lines. The anti-cancer effect was stronger than the effect of the combination of HDAC and GSK-3β inhibitors. The same doses of Metavert did not affect survival of normal hepatocytes and pancreatic ductal cells. Metavert decreased the survival of CTCs. Metavert increased histone acetylation, inhibited GSK-3β activity, decreased expression of markers of EMT/ metastasis and cancer stemness, and prevented migration of the cancer cell lines and CTCs. Furthermore, Metavert sensitized PDAC cells and CTCs to gemcitabine and radiotherapy as well. Treatment with Metavert significantly increased KPC mice survival by ~50%. Histologic examination showed that Metavert treatment inhibited formation of both early pancreatic intraepithelial neoplasia (PanIN) lesions and late lesions (carcinoma) in the pancreas of these animals. Distal metastasis was decreased from 29% in control KPC mice to 0% in Metavert treated KPC mice. Fibrosis and M2 macrophages levels were decreased in Metavert treated mice. Conclusion: We have designed and synthesized a novel drug that shows a significant anti-cancer effect in vitro in PDAC cells and CTCs and in the most aggressive mouse model of experimental PDAC. Importantly, Metavert increased the survival of KPC mice and prevented metastasis in vivo with no significant toxicity to normal cells. Pre-clinical toxicity studies are ongoing and the drug is expected to be approved for clinical testing within one year.
Biography

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version